SUVN-502#39;s clinical trial data assumed significance as no new Alzheimer#39;s drug has been approved since Forest Labs#39; Namenda in 2003
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment